Journal
CHEMICAL ENGINEERING JOURNAL
Volume 372, Issue -, Pages 483-495Publisher
ELSEVIER SCIENCE SA
DOI: 10.1016/j.cej.2019.04.140
Keywords
Synergistic therapy; Nanotheranostics; NSCLC; Erlotinib; Near-infrared fluorescence imaging; PDT therapy
Categories
Funding
- National Natural Science Foundation of China [81871481, 81571802]
- Ministry of Science and Technology of China [2015CB931804]
- Natural Science Foundation of Fujian Province [2016J06020]
- Fujian Provincial Youth Top-notch Talent Support Program
- Educational Reform Project of Fuzhou University [0360-50010865]
Ask authors/readers for more resources
The clinical outcome of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors is limited by the ambiguous molecular subtypes of non-small cell lung cancer (NSCLC) patients and the emergence of drug-resistance. Here, a nanotheranostic agent ECMI, which is indocyanine green (ICG)-loaded mesoporous silica nanoparticles lidded with ZnO QDs and wrapped with erlotinib-modified chitosan, was developed for accurately determination of molecular subtypes and synergistic therapy. The erlotinib could guide ECMI into EGFR-mutated NSCLC cells and acquire a pH/redox dual-responsive release of ICG for precise fluorescent imaging. The ECMI could exert synergistic photodynamic/molecular targeted therapeutic effects under near-infrared irradiation in either erlotinib-sensitive or erlotinib-resistant EGFR-mutated NSCLC cells. In vivo experiments further showed that ECMI had distinct distribution behaviors in different NSCLC models and demonstrated synergistic anticancer effects. These results indicated that ECMI could be a promising nanotheranostic agent to treat EGFR-mutated NSCLC, and could provide a new perspective for individualized treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available